Jun 2026 (Q2 FY26) — Aug 6, 2026
Denali Therapeutics Q2 FY26 — AVLAYAH Launch and Pipeline Advancement
Read the full callDenali Therapeutics (DNLI) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Denali Therapeutics earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 3.6 | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. The year-earlier figure was zero or a loss, so no percentage is shown. | |
| Operating margin | -3622.1 | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. | |
| Net profit | -128 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$18.34 +2.63% · +$0.47
Performance +20.6% 1Y
1Y: $15.21 on 14 Oct 2025 → $18.34. High $27.21 (9 Jul 2026), low $14.41 (6 Nov 2025).
- Previous close
- $17.87
- 52-week range
- $14.41 – $27.21
- One year
- +12.45%
Overview
- Symbol
- DNLI
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Denali Therapeutics earnings calls (DNLI)
Financials
What the filings say
Net profit, year on year: −3% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | — | 0 | — | — | — | 4 |
| Expenses | — | — | — | 135 | — | — | — | 134 |
| Operating profit | -123 | -130 | -146 | -135 | -137 | -137 | -137 | -131 |
| Operating margin | — | — | — | — | — | — | — | −3622.1% |
| Net profit | -107 | -115 | -133 | -124 | -127 | -129 | -128 | -128 |
| EPS ($ per share) | -0.63 | — | -0.78 | -0.72 | -0.74 | — | -0.69 | -0.68 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 2 | 2 | 2 | 2 | — | — |
| Reserves | -228 | -426 | -354 | -645 | -971 | -1,116 | -1,539 | -2,052 |
| Total liabilities | 115 | 158 | 454 | 442 | 418 | 123 | 144 | 131 |
| Fixed assets | 25 | 47 | 41 | 39 | 44 | 46 | 55 | 52 |
| Investments | 387 | 336 | 963 | 572 | 1,118 | 907 | 657 | 663 |
| Total assets | 662 | 553 | 1,604 | 1,404 | 1,460 | 1,154 | 1,374 | 1,145 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 50 | -152 | 416 | -211 | -245 | -358 | -348 | -413 |
| Cash from investing | -287 | 148 | -623 | -22 | -141 | 249 | -89 | 255 |
| Cash from financing | 97 | 6 | 635 | 19 | 311 | 18 | 484 | 189 |
| Net cash flow | — | — | 428 | -214 | -75 | -91 | 48 | 32 |
| Capital expenditure | -3 | -18 | -3 | -8 | -18 | -13 | -16 | -10 |
| Free cash flow | 47 | -169 | 413 | -220 | -263 | -371 | -364 | -422 |
Insider filings
20 filings between Nov 4, 2025 and Sep 4, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$1.30M
7 sales by 4 insiders
43% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 12
- Award — granted as compensation
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Watts Ryan J. | — | $580.8K | Jan 6, 2026 |
| Schuth Alexander O. | — | $420.6K | Sep 1, 2026 |
| Thornberry Nancy | — | $261.9K | Sep 2, 2026 |
| Chin Peter Scott | — | $36.9K | Sep 4, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 4, 2026 | Chin Peter Scott Chief Medical Officer | Sale | 1,654 | $36.9K |
| Sep 2, 2026 | Thornberry Nancy Director | Sale 10b5-1 plan | 10,824 | $247.3K |
| Sep 2, 2026 | Thornberry Nancy Director | Sale 10b5-1 plan | 615 | $14.6K |
| Sep 1, 2026 | Schuth Alexander O. COFO and Secretary | Sale 10b5-1 plan | 2,768 | $64.9K |
| Aug 12, 2026 | Watts Ryan J. President and CEO | Gift | 32,220 | $0 |
| Aug 11, 2026 | Schuth Alexander O. COFO and Secretary | Sale | 2,857 | $71.6K |
| Jun 3, 2026 | Cook Jennifer E. Director | Award | 6,408 | $0 |
| Jun 3, 2026 | Thornberry Nancy Director | Award | 6,408 | $0 |
| Jun 3, 2026 | Van Hauwermeiren Timothy Director | Award | 6,408 | $0 |
| Jun 3, 2026 | FLATLEY JAY T Director | Award | 6,408 | $0 |
| Jun 3, 2026 | BAKER BROS. ADVISORS LP Director | Award | 6,408 | $0 |
| Jun 3, 2026 | BAKER BROS. ADVISORS LP Director | Award | 6,408 | $0 |
| Jun 3, 2026 | Klein Peter S Director | Award | 6,408 | $0 |
| Jun 3, 2026 | Schenkein David P Director | Award | 6,408 | $0 |
| Jun 3, 2026 | Krognes Steve E. Director | Award | 6,408 | $0 |
| Jan 6, 2026 | Watts Ryan J. President and CEO | Sale | 35,198 | $580.8K |
| Jan 6, 2026 | Schuth Alexander O. COFO and Secretary | Sale | 17,218 | $284.1K |
| Jan 3, 2026 | Schuth Alexander O. COFO and Secretary | Award | 57,700 | $0 |
| Jan 3, 2026 | Watts Ryan J. President and CEO | Award | 78,960 | $0 |
| Nov 4, 2025 | Van Hauwermeiren Timothy Director | Award | 10,632 | $0 |
| Sep 3, 2025 | Watts Ryan J. President and CEO | Gift | 50,000 | $0 |
| Aug 13, 2025 | Ho Carole Chief Medical Officer | Sale 10b5-1 plan | 806 | $11.8K |
| Aug 12, 2025 | Schuth Alexander O. COFO and Secretary | Sale | 2,937 | $39.9K |
| Aug 12, 2025 | Ho Carole Chief Medical Officer | Sale 10b5-1 plan | 2,937 | $39.9K |
| Aug 5, 2025 | Ho Carole Chief Medical Officer | Option exercise | 44,655 | $30.4K |
| Jul 9, 2025 | Watts Ryan J. President and CEO | Sale 10b5-1 plan | 495,282 | $7.43M |
| Jul 9, 2025 | Watts Ryan J. President and CEO | Option exercise 10b5-1 plan | 40,000 | $211.2K |
| Jul 9, 2025 | Watts Ryan J. President and CEO | Option exercise 10b5-1 plan | 455,282 | $309.6K |
| Jun 3, 2025 | Schenkein David P Director | Award | 6,037 | $0 |
| Jun 3, 2025 | Krognes Steve E. Director | Award | 6,037 | $0 |
| Jun 3, 2025 | Klein Peter S Director | Award | 6,037 | $0 |
| Jun 3, 2025 | BAKER BROS. ADVISORS LP Director | Award | 10,565 | $0 |
| Jun 3, 2025 | Cook Jennifer E. Director | Award | 6,037 | $0 |
| Jun 3, 2025 | BAKER BROS. ADVISORS LP Director | Award | 10,565 | $0 |
| Jun 3, 2025 | FLATLEY JAY T Director | Award | 6,037 | $0 |
| Jun 3, 2025 | Tessier-Lavigne Marc Director | Award | 6,037 | $0 |
| Jun 3, 2025 | Thornberry Nancy Director | Award | 6,037 | $0 |
| Jan 7, 2025 | Krognes Steve E. Director | Sale | 3,339 | $69.5K |
| Jan 7, 2025 | Watts Ryan J. President and CEO | Sale | 7,650 | $159.2K |
| Jan 7, 2025 | Schuth Alexander O. COFO and Secretary | Sale | 2,907 | $60.5K |
| Jan 7, 2025 | Ho Carole Chief Medical Officer | Sale | 2,907 | $60.5K |
| Jan 6, 2025 | Schuth Alexander O. COFO and Secretary | Sale | 12,255 | $247.8K |
| Jan 6, 2025 | Ho Carole Chief Medical Officer | Sale | 12,255 | $247.8K |
| Jan 6, 2025 | Watts Ryan J. President and CEO | Sale | 29,266 | $591.8K |
| Jan 3, 2025 | Schuth Alexander O. COFO and Secretary | Award | 54,180 | $0 |
| Jan 3, 2025 | Watts Ryan J. President and CEO | Award | 54,180 | $0 |
| Jan 3, 2025 | Ho Carole Chief Medical Officer | Award | 54,180 | $0 |
| Jan 2, 2025 | SATO VICKI L Director | Sale 10b5-1 plan | 3,080 | $64.4K |
| Dec 31, 2024 | Krognes Steve E. Director | Sale 10b5-1 plan | 30,000 | $607.5K |
| Dec 27, 2024 | Schuth Alexander O. COFO and Secretary | Option exercise | 6,708 | $35.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Denali Therapeutics Inc.
Free account. Everything above stays public.
Write why you follow Denali Therapeutics Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading